You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Claims for Patent: 8,236,306

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,236,306

Title:	Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
Abstract:	A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispinal space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position.
Inventor(s):	Tobinick; Edward Lewis (Santa Monica, CA)
Assignee:
Application Number:	12/568,661
Patent Claims:	1. A method for delivering a biologic to a human, comprising: administering said biologic parenterally into the perispinal space of said human without direct intrathecal or epidural injection and then positioning said human in a Trendelenburg position. 2. The method of claim 1, wherein said biologic is etanercept. 3. The method of claim 1, wherein said biologic is golimumab. 4. The method of claim 1, wherein said biologic is Gammagard. 5. The method of claim 1, wherein said biologic is bapineuzumab. 6. The method of claim 1, wherein said human has neck pain. 7. The method of claim 1, wherein said human has cervical radiculopathy. 8. The method of claim 1, wherein said human has degenerative disc disease. 9. The method of claim 1, wherein said human has fibromyalgia. 10. The method of claim 1, wherein said human has neuropathic pain. 11. The method of claim 1, wherein said human has sciatica. 12. The method of claim 1, wherein said human has low back pain.

Details for Patent 8,236,306

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	GAMMAGARD, GAMMAGARD S/D, IVEEGAM	immune globulin intravenous (human)	For Injection	103133	February 18, 1986	⤷ Start Trial	2029-10-19
Takeda Pharmaceuticals U.s.a., Inc.	GAMMAGARD, GAMMAGARD S/D, IVEEGAM	immune globulin intravenous (human)	For Injection	103133	July 27, 2000	⤷ Start Trial	2029-10-19
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Start Trial	2029-10-19
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Start Trial	2029-10-19
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Start Trial	2029-10-19
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Start Trial	2029-10-19
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	⤷ Start Trial	2029-10-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,236,306

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2003287045	⤷ Start Trial
Australia	2604301	⤷ Start Trial
Australia	2616100	⤷ Start Trial
Australia	758523	⤷ Start Trial
Canada	2364130	⤷ Start Trial
European Patent Office	1161260	⤷ Start Trial
Japan	2002537356	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.